We are live on
!
Find out more
Rockefeller Capital Management Portfolio holdings
AUM
$56.4B
1-Year Est. Return
24.96%
This Fund
S&P 500
This Quarter
Est. Return
+16.85%
1 Year Est. Return
+24.96%
3 Year Est. Return
+83.53%
5 Year Est. Return
+100.91%
10 Year Est. Return
–
AUM
$13.2B
AUM Growth
+$2.53B
(+24%)
Cap. Flow
+$1B
Cap. Flow
% of AUM
7.59%
Top 10 Holdings %
Top 10 Hldgs %
23.93%
Holding
3,118
New
401
Increased
1,400
Reduced
617
Closed
168
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$120M |
| 2 |
Globe Life
GL
|
+$115M |
| 3 |
MPT
Medical Properties Trust
MPT
|
+$91.5M |
| 4 |
Arch Capital
ACGL
|
+$69.2M |
| 5 |
Amazon
AMZN
|
+$45.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progressive
PGR
|
+$138M |
| 2 |
GSK
GSK
|
+$98.7M |
| 3 |
Crown Holdings
CCK
|
+$92.3M |
| 4 |
American Water Works
AWK
|
+$54M |
| 5 |
SolarEdge
SEDG
|
+$45.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.64% |
| 2 | Financials | 15.05% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 9.61% |
| 5 | Communication Services | 7.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
iShares Select Dividend ETF
DVY
$23.6B
| $10.6M | 0.08% |
109,894
+36,461
| +50% | +$3.31M |
|
227
VF Corp
VFC
$5.89B
| $10.5M | 0.08% |
122,513
-18,949
| -13% | -$1.51M |
|
228
Novartis
NVS
$297B
| $9.83M | 0.07% |
104,127
-47,264
| -31% | -$4.13M |
|
229
DexCom
DXCM
$32B
| $9.75M | 0.07% |
105,448
-16,068
| -13% | -$1.43M |
|
230
Wells Fargo
WFC
$264B
| $9.38M | 0.07% |
310,750
-109,917
| -26% | -$2.85M |
|
231
CSX Corp
CSX
$93.1B
| $9.27M | 0.07% |
306,426
+73,308
| +31% | +$2.11M |
|
232
abrdn Physical Precious Metals Basket Shares ETF
GLTR
$2.67B
| $9.01M | 0.07% |
91,010
+25,529
| +39% | +$2.43M |
|
233
iShares S&P Mid-Cap 400 Growth ETF
IJK
$11.2B
| $8.89M | 0.07% |
123,046
-5,414
| -4% | -$361K |
|
234
Invesco S&P 500 Equal Weight ETF
RSP
$99.5B
| $8.88M | 0.07% |
69,602
+10,748
| +18% | +$1.28M |
|
235
Vanguard Financials ETF
VFH
$13.6B
| $8.84M | 0.07% |
121,306
-1,171
| -1% | -$77.3K |
|
236
3M
MMM
$94.3B
| $8.78M | 0.07% |
60,049
+23,817
| +66% | +$3.38M |
|
237
KKR & Co
KKR
$92.3B
| $8.77M | 0.07% |
216,716
-4,490
| -2% | -$170K |
|
238
WisdomTree Emerging Markets ex-State-Owned Enterprises Fund
XSOE
$2.09B
| $8.76M | 0.07% |
220,922
-3,323
| -1% | -$122K |
|
239
Unilever
UL
$136B
| $8.75M | 0.07% |
128,824
+70,529
| +121% | +$4.79M |
|
240
Equinix
EQIX
$103B
| $8.74M | 0.07% |
12,234
+5,748
| +89% | +$4.28M |
|
241
Netflix
NFLX
$309B
| $8.71M | 0.07% |
161,030
+40,090
| +33% | +$2.03M |
|
242
Corning
GLW
$143B
| $8.48M | 0.06% |
235,668
+146,117
| +163% | +$5.19M |
|
243
State Street SPDR S&P Dividend ETF
SDY
$23.9B
| $8.47M | 0.06% |
79,967
-795
| -1% | -$80.4K |
|
244
Vanguard Morningstar Value ETF
VTV
$191B
| $8.4M | 0.06% |
70,667
+15,952
| +29% | +$1.79M |
|
245
KLA
KLAC
$259B
| $8.4M | 0.06% |
324,500
+87,370
| +37% | +$2.04M |
|
246
iShares S&P Mid-Cap 400 Value ETF
IJJ
$8.97B
| $8.38M | 0.06% |
97,117
+1,363
| +1% | +$107K |
|
247
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $8.37M | 0.06% |
59,467
+56,148
| +1,692% | +$7.19M |
|
248
Ecolab
ECL
$79.9B
| $8.31M | 0.06% |
38,432
+10,558
| +38% | +$2.21M |
|
249
Toronto Dominion Bank
TD
$200B
| $8.23M | 0.06% |
145,831
-12,800
| -8% | -$649K |
|
250
ConocoPhillips
COP
$141B
| $8.21M | 0.06% |
205,437
+135,070
| +192% | +$4.98M |
|
Similar funds
NAMI
Rockefeller Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Rockefeller Capital Management held 3,118 positions worth $13.2B, up 24% from $10.7B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rockefeller Capital Management deployed $1B of net new capital in Q4 2020, opening 401 new positions and adding to 1,400 existing holdings. Its largest new stake was BridgeBio Pharma: 777,031 shares worth $55.3M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Progressive, an estimated $138M trimmed.
- Rockefeller Capital Management's largest Q4 2020 buy was BridgeBio Pharma: 777,031 shares worth $55.3M.
- Rockefeller Capital Management added most to Alibaba in Q4 2020, an estimated $120M increase.
- Rockefeller Capital Management's biggest Q4 2020 reduction was Progressive, cutting an estimated $138M.
- Rockefeller Capital Management fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $1.67M.
- Rockefeller Capital Management's ten largest holdings make up 24% of its $13.2B portfolio in Q4 2020.
- Rockefeller Capital Management opened 401 new positions and closed 168 in Q4 2020.
- Rockefeller Capital Management's portfolio value rose 24% quarter-over-quarter to $13.2B.
Based on Rockefeller Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.